Studio finanziato dalla Brain Research Foundation Verona.
Articolo pubblicato online il 20 febbraio 2022: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00072-X/fulltext
© 2022 The Authors. Published by Elsevier B.V.
Alessandra Ruggiero, Chiara Piubelli, Lucia Calciano, Simone Accordini, Maria Teresa Valenti, Luca Dalle Carbonare, Donato Zipeto et al.
Background Currently, evaluation of the IgG antibodies specific for the SARS-CoV-2 Spike protein following vaccination is used worldwide to estimate vaccine response. Limited data are available on vaccine-elicited IgM antibodies and their potential implication in immunity to SARS-CoV-2.
Methods We performed a longitudinal study to quantify anti-S SARS-CoV-2 IgG and IgM (IgG-S and IgM-S) in health care worker (HCW) recipients of the BNT162b2 vaccine. Samples were collected before administration (T0), at the second dose (T1) and three weeks after T1 (T2). The cohort included 1584 immunologically nay¨ve to SARSCoV-2 (IN) and 289 with history of previous infection (PI).
Findings IN showed three patterns of responses: (a) IgG positive/IgM negative (36.1%), (b) coordinated IgM-S/IgGS responses appearing at T1 (37.4%) and (c) IgM appearing after IgG (26.3%). Coordinated IgM-S/IgG-S responses were associated with higher IgG titres. In IgM-S positive PI, 64.5% were IgM-S positive before vaccination, whereas 32% and 3.5% developed IgM-S after the first and second vaccine dose, respectively. IgM-S positive sera had higher pseudovirus neutralization titres compared to the IgM-S negative.
Interpretation Coordinated expression of IgG-S and IgM-S after vaccination was associated with a significantly more efficient response in both antibody levels and virus-neutralizing activity. The unconventional IgG-S positive/ IgM-S negative responses may suggest a recruitment of cross coronaviruses immunity by vaccination, warranting further investigation.
Responsabile: prof. Donato Zipeto – Università degli Studi di Verona
Articolo open access con licenza Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)